Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:21:00 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:YMAB - Y-MABS THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
YMAB - Q2.715.00·15.050.215.025+0.0250.2101.51,4611,20214.85  15.41  14.8520.90  4.6012:02:38Mar 1415 min RT 2¢

Recent Trades - Last 10 of 1202
Time ETExPriceChangeVolume
12:02:38Q15.02470.02471
12:02:11Q15.0250.025100
12:02:09Q15.0250.02511
12:02:03Q15.00 3
12:02:00Q15.0250.025100
12:01:51Q15.02350.02351
12:01:04Q15.02350.02351
12:00:57Q15.0220.022100
12:00:57Q15.0220.022100
12:00:16Q15.0220.0221

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-14 09:05U:YMABNews ReleaseY-mAbs Therapeutics Announces Resignation of Chief Financial Officer
2024-03-04 07:30U:YMABNews ReleaseY-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
2024-02-29 16:05U:YMABNews ReleaseY-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
2024-02-16 07:30U:YMABNews ReleaseY-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024
2024-01-02 16:05U:YMABNews ReleaseY-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-13 16:05U:YMABNews ReleaseY-mAbs Therapeutics Added to the NASDAQ Biotechnology Index
2023-11-13 16:05U:YMABNews ReleaseY-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
2023-10-31 07:05U:YMABNews ReleaseY-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023
2023-10-18 16:05U:YMABNews ReleaseY-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
2023-10-17 16:05U:YMABNews ReleaseY-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA
2023-10-16 16:05U:YMABNews ReleaseY-mAbs Announces Publication in Cancers
2023-09-21 16:05U:YMABNews ReleaseY-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology
2023-09-06 16:05U:YMABNews ReleaseY-mAbs to Participate at Upcoming Investor Conferences in September
2023-08-10 16:05U:YMABNews ReleaseY-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
2023-08-02 16:05U:YMABNews ReleaseY-mAbs to Participate at Upcoming Investor Conferences
2023-08-01 16:05U:YMABNews ReleaseY-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023
2023-05-26 09:00U:YMABNews ReleaseY-mAbs Announces Presentation of Naxitamab Data at ASCO
2023-05-26 09:00U:YMABNews ReleaseY-mAbs Announces Presentation of GD2-SADA Study at ASCO
2023-05-23 09:00U:YMABNews ReleaseY-mAbs ¢ € ™ DANYELZA ‚ ® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil
2023-05-08 16:01U:YMABNews ReleaseY-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance